FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burd	len								
hours per response:	0.5								

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Sheridan William P  (First) (Middle)						BIOCRYST PHARMACEUTICALS INC [ BCRX ]								ationship of Reportir k all applicable) Director Officer (give title below)		ng Person(s) to Issue 10% Owr Other (sp below)		ner	
(Last) (First) (Middle) 4505 EMPEROR BLVD. SUITE 200				01	1/01/2								SR VP - CMO						
(Street) DURHAM NC 27703					_	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person  Form filed by More than One Reporting Person  Person					
(City)	(S	itate)	(Zip)																
1. Title of Security (Instr. 3) 2. Trans					nsactio	action 2A. Deemed Execution Day/Year) (Month/Day/Year)		3. 4. Secur Transaction Dispose Code (Instr.		4. Securiti	es Acquire Of (D) (Inst	d (A) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Transact	Transaction(s) (Instr. 3 and 4)			(1130.4)	
Common	Stock			01/0	/01/2013				A		8,500 <sup>(1)</sup> A		\$0	56,156			D		
Common	Stock			01/0	01/20	13			A	8,500 <sup>(2)</sup> A \$0 64,656 D		D							
			Table II -				urities <i>A</i> ls, warra							Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	ate,	4. Transa Code ( 8)		Derivative		6. Date Exercis Expiration Date (Month/Day/Ye		e	7. Title an of Securit Underlyin Derivative (Instr. 3 a	g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)			Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(S)			
Emp. Stock Option (Right to Buy)	\$1.42	01/01/2013			A		50,000 <sup>(3)</sup>		01/01/20	014	01/01/2023	Common Stock	50,000	\$0	50,00	00	D		
Emp. Stock Option (Right to	\$1.42	01/01/2013			A		50,000 <sup>(4)</sup>		01/01/20	014	01/01/2023	Common Stock	50,000	\$0	50,00	00	D		

## Explanation of Responses

- $1.\ Retention\ Restricted\ stock\ Award.\ Will\ vest\ 50\%\ on\ each\ of\ the\ first\ and\ second\ anniversaries\ of\ the\ date\ of\ grant.$
- 2. Annual Employee Restricted Stock Award. Will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- 3. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- 4. Retention Employee Stock Option becomes exercisable at a rate of 50% on each of the first and second anniversaries of the date of grant.

/s/ Alane Barnes, by power of attorney 01/04/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.